Option to Acquire Haibo Technology Signals Abyrx’s Entry into Soft Tissue Hemostasis Market

Abyrx™, Inc., has announced it has entered the soft tissue hemostasis market with a commercial deal with Chinese company Haibo Biotechnology Institute’s (HBI) proprietary resorbable plant-derived soft tissue hemostat technology platform.

Most read

Latest

^